Payment overview · 2025
General Payments
$296.53
13 reported records · 10 companies
Healthcare provider profile · identity verified
Scott W Mercer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ENCINITAS, CA · NPI 1295736031
Verified facts
What the public records show
CMS Open Payments records show Scott W Mercer, M.D. received $296.53 in general payments during 2025 across 13 reported records.
PFIZER INC. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.35 | 17.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.62 | 17.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.75 | 14.8% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.20 | 9.2% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $23.43 | 7.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.36 | 7.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.23 | 7.8% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $21.85 | 7.4% | 1 | 2025 |
| Lucid Diagnostics Inc. | Unresolved — no canonical attribution shown | $17.47 | 5.9% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $14.27 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $296.53 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.35 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 76 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 189 | 56 |
| Alprazolam | Alprazolam | 187 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 155 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 125 | 38 |
| Lisinopril | Lisinopril | 124 | 33 |
| Simvastatin | Simvastatin | 124 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 35 |
| Losartan Potassium | Losartan Potassium | 108 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 27 |
| Metformin Hcl | Metformin Hcl | 103 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 90 | 24 |
| Gabapentin | Gabapentin | 82 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 23 |
| Eliquis | Apixaban | 76 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 28 |
| Omeprazole | Omeprazole | 71 | 25 |
| Trazodone Hcl | Trazodone Hcl | 70 | 23 |
| Lorazepam | Lorazepam | 59 | 13 |
| Synthroid | Levothyroxine Sodium | 55 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 37 |
| Finasteride | Finasteride | 48 | 13 |
| Furosemide | Furosemide | 48 | 18 |
| Tramadol Hcl | Tramadol Hcl | 44 | 12 |
| Estradiol | Estradiol | 43 | 15 |
| Ozempic | Semaglutide | 43 | suppressed |
| Temazepam | Temazepam | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Allopurinol | Allopurinol | 38 | 11 |
| Sertraline Hcl | Sertraline Hcl | 37 | 12 |
| Acyclovir | Acyclovir | 36 | 13 |
| Clonazepam | Clonazepam | 36 | 13 |
| Azithromycin | Azithromycin | 35 | 30 |
| Celecoxib | Celecoxib | 35 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | 15 |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Prednisone | Prednisone | 27 | 19 |
| Valacyclovir | Valacyclovir Hcl | 27 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 22 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 19 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 14 |
| Atenolol | Atenolol | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 13 |
| Famotidine | Famotidine | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 13 |
| Diazepam | Diazepam | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $296.53 · 13 records | PFIZER INC. | AIRSUPRA, BREZTRI, ELIQUIS, EVENITY, Fluad, Flucelvax, JATENZO, MOUNJARO, PROLIA, Tlando, WatchPATONE, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error